These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16498513)

  • 1. The vascular effects of cilostazol.
    Weintraub WS
    Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):56B-60B. PubMed ID: 16498513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilostazol in the management of vascular disease.
    Dalainas I
    Int Angiol; 2007 Mar; 26(1):1-7. PubMed ID: 17353881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
    Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
    Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.
    Douglas JS; Weintraub WS; Holmes D
    Clin Cardiol; 2003 Oct; 26(10):451-4. PubMed ID: 14579914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilostazol and peripheral arterial disease.
    Pearce L; Ghosh J; Counsell A; Serracino-Inglott F
    Expert Opin Pharmacother; 2008 Oct; 9(15):2683-90. PubMed ID: 18803454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
    Dindyal S; Kyriakides C
    Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):6-14. PubMed ID: 19149700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilostazol: treatment of intermittent claudication.
    Reilly MP; Mohler ER
    Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
    Inoue T; Uchida T; Sakuma M; Imoto Y; Ozeki Y; Ozaki Y; Hikichi Y; Node K
    J Am Coll Cardiol; 2004 Oct; 44(7):1408-14. PubMed ID: 15464320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
    Ikeda Y
    Thromb Haemost; 1999 Aug; 82(2):435-8. PubMed ID: 10605734
    [No Abstract]   [Full Text] [Related]  

  • 10. The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis.
    Sohn M; Lim S
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis.
    Morishita R
    Atheroscler Suppl; 2005 Dec; 6(4):41-6. PubMed ID: 16275167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cilostazol].
    Inoue T
    Nihon Rinsho; 2016 Jun; 74 Suppl 4 Pt 1():393-9. PubMed ID: 27534202
    [No Abstract]   [Full Text] [Related]  

  • 13. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats.
    Tani T; Uehara K; Sudo T; Marukawa K; Yasuda Y; Kimura Y
    Atherosclerosis; 2000 Oct; 152(2):299-305. PubMed ID: 10998457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilostazol: a review of its use in intermittent claudication.
    Chapman TM; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(2):117-38. PubMed ID: 14727939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
    Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
    Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials).
    Lee SW; Ahn JM; Han S; Park GM; Cho YR; Lee WS; Jang JY; Kwon CH; Lee JY; Kim WJ; Kang SJ; Kim YH; Lee CW; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2013 Nov; 112(9):1328-34. PubMed ID: 23890573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet treatment with cilostazol after stent implantation.
    Yoshitomi Y; Kojima S; Sugi T; Yano M; Matsumoto Y; Kuramochi M
    Heart; 1998 Oct; 80(4):393-6. PubMed ID: 9875121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilostazol in the management of atherosclerosis.
    Sallustio F; Rotondo F; Di Legge S; Stanzione P
    Curr Vasc Pharmacol; 2010 May; 8(3):363-72. PubMed ID: 20180773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial.
    Weintraub WS; Foster J; Culler SD; Becker ER; Parker K; Zhang Z; Kolm P; Douglas JS;
    J Invasive Cardiol; 2004 May; 16(5):257-9. PubMed ID: 15152132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.